Want to see PSNL full AI Analyst Report?
PSNL Stock Chart & Stats
$17.25
$0.26(2.21%)
At close: 4:00 PM EDT
$17.25
$0.26(2.21%)
Day’s Range― - ―
52-Week Range$4.96 - $18.89
Previous CloseN/A
Volume3.24M
Average Volume (3M)2.23M
Market Cap
$1.70B
Enterprise Value$1.24B
Total Cash (Recent Filing)$212.66M
Total Debt (Recent Filing)$38.00M
Price to Earnings (P/E)―
Beta1.14
Next Earnings
Nov 10, 2026EPS Estimate
-0.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.09
Shares Outstanding106,799,870
10 Day Avg. Volume2,926,427
30 Day Avg. Volume2,234,073
Financial Highlights & Ratios
PEG Ratio0.26
Price to Book (P/B)2.72
Price to Sales (P/S)10.20
P/FCF Ratio-8.94
Enterprise Value/Market Cap0.73
Enterprise Value/Revenue17.77
Enterprise Value/Gross Profit140.08
Enterprise Value/Ebitda-12.73
Forecast
1Y Price Target
$16.25Price Target Upside-5.80% Downside
Rating ConsensusHold
Number of Analyst Covering4
EPS Forecast (FY)-1.09
Revenue Forecast (FY)$82.20M
Bulls Say, Bears Say
Bulls Say
Strategic Merger ProgressThe merger’s regulatory progress increases the likelihood that Personalis will join Tempus, potentially adding Tempus’s scale, data and AI-enabled commercialization to its oncology testing platform. That could broaden market access and support durable adoption, although shareholder approval and other closing conditions remain.
Government-backed Contract VisibilityThe additional VA funding reinforces Personalis’ position in a large, government-backed genomics program and provides a meaningful source of contracted demand. Continued participation can improve revenue visibility, deepen public-sector relationships, and support longer-term credibility in precision medicine.
Manageable LeverageLow leverage gives Personalis more balance-sheet flexibility than its weak earnings profile would otherwise suggest. Limited debt reduces interest and refinancing pressure, preserving more strategic room to pursue partnerships, support operations, or invest in growth while the company works to stabilize profitability.
Bears Say
Revenue And Gross-profit DeteriorationThe sharp revenue decline, following earlier modest growth, signals weakened commercial momentum in the core testing and analysis business. Negative gross profit also indicates current service economics are unfavorable, making sustainable scaling harder and increasing pressure to improve pricing, utilization, or operating efficiency.
Sustained Cash BurnMaterial operating and free-cash-flow losses show that Personalis is consuming significant cash to run the business. Continued burn can restrict investment capacity and make progress dependent on external funding until margins and operating costs improve, reducing financial resilience over the next several quarters.
Large Losses Eroding CapitalLosses of this scale relative to revenue demonstrate that the company has not yet established a sustainable earnings model. Persistently negative returns reduce shareholder value and can further shrink the capital base, leaving less financial support for innovation, commercialization, and future expansion.
Personalis News
PSNL FAQ
What was Personalis Inc’s price range in the past 12 months?
Personalis Inc lowest stock price was $4.96 and its highest was $18.89 in the past 12 months.
What is Personalis Inc’s market cap?
Personalis Inc’s market cap is $1.70B.
When is Personalis Inc’s upcoming earnings report date?
Personalis Inc’s upcoming earnings report date is Nov 10, 2026 which is in 20 days.
How were Personalis Inc’s earnings last quarter?
Personalis Inc released its earnings results on Aug 04, 2026. The company reported -$0.3 earnings per share for the quarter, missing the consensus estimate of -$0.263 by -$0.037.
Is Personalis Inc overvalued?
According to Wall Street analysts Personalis Inc’s price is currently Overvalued.
Does Personalis Inc pay dividends?
Personalis Inc does not currently pay dividends.
What is Personalis Inc’s EPS estimate?
Personalis Inc’s EPS estimate is -0.26.
How many shares outstanding does Personalis Inc have?
Personalis Inc has 106,799,870 shares outstanding.
What happened to Personalis Inc’s price movement after its last earnings report?
Personalis Inc reported an EPS of -$0.3 in its last earnings report, missing expectations of -$0.263. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Personalis Inc?
Currently, no hedge funds are holding shares in PSNL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Personalis Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$16.25 (-5.80% Downside)
$16.25 (-5.80% Downside)
Blogger Sentiment
Neutral
PSNL Sentiment 61%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Increased
By 449.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $266.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.8%
Last 30 Days ▼ 9.9%
Last 30 Days ▼ 9.9%
Technicals
SMA
Positive
20 days / 200 days
Momentum
57.50%
12-Months-Change
Fundamentals
Return on Equity
-46.47%
Trailing 12-Months
Asset Growth
20.66%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Personalis Inc
Personalis, Inc. operates globally as a specialized cancer genomics firm. The company delivers advanced sequencing and data analysis capabilities, primarily supporting the development of novel cancer treatments and facilitating extensive genetic research initiatives. Central to their offerings is the NeXT Platform, which enables detailed data analysis of tumors and their surrounding immune microenvironments, even from small tissue or plasma samples. This platform encompasses several specialized solutions: ImmunoID Next for tissue-based tumor profiling; NeXT Liquid Biopsy for plasma analysis; NeXT Personal, a specific liquid biopsy designed for individual patient tumor tracking; the NeXT Dx Test, a genomic cancer profiling tool that identifies composite biomarkers for treatment guidance; and the sophisticated NeXT SHERPA and NeXT NEOPS for predicting neoantigens. Additionally, Personalis offers the ACE platform, utilized for diverse clinical and therapeutic applications like neoantigen prediction, biomarker identification, and the selection of new drug targets. Their clientele includes biopharmaceutical companies, academic institutions, non-profit organizations, and government entities. The company has established significant partnerships with organizations such as Mayo Clinic, MapKure, LLC, SpringWorks Therapeutics, Inc., and Moores Cancer Center. Personalis, Inc. was founded in 2011 and is based in Menlo Park, California.
PSNL Stock 12 Month Forecast
Average Price Target
$16.25
▼(-5.80% Downside)
Technical Analysis
Ownership Overview
12.99% Insiders
11.36% Mutual Funds
0.06% Other Institutional Investors
64.09% Public Companies and
Individual Investors